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Background  
Diabetes mellitus type 1 (T1DM) is a complex 
disease resulting from the interplay of genetic, 
epigenetic, and environmental factors.1 Worldwide, 
T1DM epidemic represents an increasing global 
public health burden, and the incidence of T1DM 
among children has been rising2 with an overall 
incidence of ∼3% to 5% per year, and it is 
estimated that there are ∼65. 000 new cases per 
year in children under 15 years old.3 This 
significant worldwide increase in the incidence of 
T1DM suggests the importance of interactions 
between genetic predisposition and environmental 
factors in the multifactorial etiology of T1DM.4 
 
Pathophysiology of type 1 diabetes mellitus: role 
of pro-inflammatory cytokines 
Type 1 diabetes mellitus (T1DM) is an autoimmune 
disease characterized by the destruction of insulin-
producing β-cells in the pancreatic islets of 
Langerhans (Fig.1), which is mediated by 
autoreactive T cells, macrophages and pro-
inflammatory cytokines (Fig.2). This leads to an 
inability to produce sufficient insulin resulting in 
elevated blood glucose levels and pathological 
effects5. 
T1DM is believed to be initiated by 
physiological β-cell death or islet injury triggering 
the homing of macrophages and dendritic cells that 
in turn launch an inflammatory reaction. 
The infiltrating macrophages secrete pro-
inflammatory cytokines, namely interleukin-1β (IL-
1β) and tumour necrosis factor α (TNF α) as well as 
various chemokines that attract immune cells such 
as dendritic cells, macrophages and T lymphocyte. 
T cells recognizing β-cell-specific antigens become 
activated, infiltrate the inflamed islets and attack the 
β-cells6,7. 
In a normally functioning immune system, T 
cells with a high affinity for self-antigens are 
eliminated during their differentiation resulting in 
immune ‘tolerance’. Autoreactive cells that have 
escaped these mechanisms are subject to ‘peripheral 
immune regulation’ that blocks their activation and 
clonal expansion, preventing development of an 
autoimmune disease8. For reasons we do not fully 
understand, these immune regulatory mechanisms 
either fail to launch, or are ineffective in stopping 
the immune attack against the β-cells in T1DM, and 
a positive feedback cycle is established8. This 
forward-feeding process of T cell- and cytokine-
mediated β-cell killing can be ongoing for years 
progressively destroying the β-cells. When over 80 
% of the β-cells are deleted by this continuous T 
lymphocyte and inflammatory cytokine-driven 
attack the insulin secretory capacity falls below a 
certain threshold and the disease manifests itself. 
Activated T cells induce death of a target cell 
by (1) secreting perforin and granzymes, (2) 
releasing pro-inflammatory cytokines including 
interferon-γ (IFN γ) and TNF or (3) activation of 
Fas receptors on the surface of target cells. All 
these factors have also been described to contribute 
to β-cell killing in T1DM9.  In particular, recent 
evidence suggests that the cause stress in β-cells 
which eventually activates the cell’s death 
machinery. The signal transduction pathways 
activated by these pro-inflammatory cytokines 
leading to chemokine secretion, β-cell stress and 
death are detailed below. It is very important to 
note that any of the above pro-inflammatory 
cytokines alone has limited effects in terms of cell 
stress or death, on β-cells. However, combinations 
of IL-1β/ or TNF α/IFN γ have very strong, 
synergistic effects that trigger serious levels of 
stress culminating in cell death. 
Atopy is the development of adverse 
hypersensitivity immune reactions against 
environmental antigens, usually associated with 
immunoglobulin E, and includes atopic dermatitis, 
asthma, allergic rhinitis, allergic conjunctivitis and 
food allergy10.  The prevalence of allergic diseases 
has increased in the world as a whole, particularly 
in developing countries11. 
 
The relationship between the expression of 
allergic and autoimmune diseases 
There has been considerable interest in defining the 
relationship between the expression of allergic and 
autoimmune diseases in populations of patients 
(Fig.3). Are patients with autoimmune disease 
‘protected’ from developing allergic 
[immunoglobulin E (IgE)-mediated] diseases? Does 




risk of the subsequent development of autoimmune 
diseases? Although there are clinical studies 
addressing this question, methodological problems, 
particularly in identification of atopic subjects, 
limits their usefulness. Moreover, an immune-based 
explanation of the observed epidemiological 
findings has relied on a paradigm that is currently 
undergoing increased scrutiny and modification to 
include genetic predisposition and its interaction 
with environmental factors, such as early endotoxin 
or mycobacterial exposure12,13. 
Until recently, the adaptive cellular immune 
response has been characterized broadly as being 
polarized in one of two directions: type 1 or type 
214. Type 1 responses, directed by T helper type 1 
(Th1) CD4+ T cells and identified by the signature 
cytokine interferon (IFN)-g, are considered to 
protect against infections by intracellular 
pathogens15, and have been incriminated in the 
pathogenesis of autoimmune diseases such as 
rheumatoid arthritis  (RA), multiple sclerosis (MS) 
and type 1 diabetes mellitus16,17. By contrast, type 2 
responses, directed by Th2 CD4+ T cells and 
identified by the signature cytokines interleukin 
(IL-4), IL-5 and IL-13, are considered to protect 
against helminthic infections18 and to play major 
pathogenic roles in allergic diseases and asthma19. 
Reciprocal counter-regulation of Th1 and Th2 
cells20 predicted that Th1-type autoimmune diseases 
and Th2-mediated allergic diseases would occur in 
mutually exclusive populations of patients. 
However, recent observations have challenged the 
validity of the long-standing Th1/Th2 paradigm21, 
and a far more complex story explaining the 
immunological basis of cellular immune-mediated 
host defense and the pathogenesis of autoimmune 
and allergic diseases is emerging. The new 
paradigm identifies additional lymphocyte subsets, 
such as Th17 T cells, regulatory T cells (Treg) and 
novel soluble factors. These help to explain 
experimental observations not predicted by the 
Th1/Th2 paradigm, and provide a new prism 
through which to examine the intersection of 
autoimmune and allergic disease21. In this review, 
we first take a critical look at the epidemiological 
literature bearing on the relationship between 
allergic diseases and type diabetes, and then 
examine the findings in the context of current 




Figure 1. Genetic, exogenous, and epigenetic predisposing factors and biomarkers in T1DM. 
Adapted from: Stankov K, Benc D, Draskovic D. Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics. 
2013 Dec;132(6):1112-22. 
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Figure 2. Pathogenic mechanisms and environmental factors that trigger T1DM onset in genetically susceptible people, 
resulting in b-cell apoptosis and diabetes. ROS, reactive oxygen species. 





Figure 3. Differentiation of and nexus between CD4+ T cell subsets. The figure depicts the diversity of CD4+ T cell 
subsets and their multiple modes of interaction. Green arrows signify positive influences and red lines inhibitory 
influences. All lines represent the activity of individual cytokines except in the case of T helper type 17 (Th17) cell 
inhibition by interferon-g and interleukin-4 where both cytokines must act in concert. The crossed green arrows with the 
question mark below indicate the potential for a Th1-specific immunomodulatory agent to reveal or exacerbate a Th2 
disease or vice versa.  
IL, interleukin; TGF, transforming growth factor; IFN, interferon. 
Adapted from: Rabin RL, Levinson AI. The nexus between atopic disease and autoimmunity: a review of the epidemiological and 
mechanistic literature. Clin Exp Immunol 2008; 153:19–30
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Animal model hypothesis of association between 
childhood type 1 diabetes and atopic disease 
In animal models, Th1 cytokines such as IFN-γ and 
IL-12 are associated with islet cell destruction22,23, 
and Th2 cytokine-secreting T cells are protective24. 
Among many known autoantigens, only pro-insulin 
and insulin are islet cell specific25. Specific T cells 
stimulated with pro-insulin peptides secrete IFN-γ, 
while cells from many controls secrete the 
regulatory cytokine IL-1026. Type 1 diabetes 
mellitus is linked strongly with HLA class II 
haplotypes, some of which predispose to disease 
and others that protect27. While the HLA linkages 
are by far the strongest immunological risk factor, 
type 1 diabetes mellitus is also associated with 
polymorphisms in non-coding regions of two 
cytokine genes, IFN-γ28 and IL-12 p4029, and an 
amino acid substitution in cytotoxic T lymphocyte 
associated molecule 4, a co-stimulatory protein 
essential for attenuating cell-mediated immunity30-
32. 
The earliest observations of an inverse 
association between diabetes mellitus and allergic 
diseases prompted many reports throughout the 
mid-20th century, those addressing subjects with 
type 1 diabetes mellitus are considered in this 
review. 
 
The Hygiene Hypothesis 
The hygiene hypothesis argues that early 
environmental stimulation by infections is 
necessary to achieve a mature and balanced 
repertoire of immune responses33. Epidemiological 
studies provide evidence that frequent exposure to 
infections early in life is protective for both 
diabetes34 and asthma35,36. 
The protective mechanisms induced by 
infection are unknown but thought to be related to 
the production of regulatory T cells. Complex 
interactions between various components of the 
immune system control the production of Th1 cells, 
which are traditionally associated with autoimmune 
disease, and Th2 cells, which are traditionally 
associated with allergic disease37. Such interactions 
could explain an inverse relationship between 
autoimmune and allergic disease such that the 
hygiene hypothesis is consistent with an inverse 
association between atopic diseases and type 1 
diabetes at the individual level, despite their 
simultaneously increasing incidence in the 
population. Such inverse associations have been 
reported for other autoimmune disorders38. 
However, the conclusion that the hygiene 
hypothesis provides the explanation for these 
inverse associations could be premature because 
there may be other shared environmental or genetic 
risk factors that predispose to one disease and 
protect against another . 
 
Literature review  
A meta-analysis concluded a ‘small but significant’ 
decrease in asthma prevalence in children with type 
1 DM39. Studies of interest are discussed below. 
Douek and colleagues used the ISAAC 
questionnaire to compare 157 probands with type 1 
diabetes mellitus to 173 unaffected siblings, and 
found that fewer type 1 diabetes mellitus subjects 
than controls had wheezed at all within 12 months 
of the study, or had multiple or speech-limiting 
episodes of wheezing40. Moreover, the frequency 
and severity of symptoms were also significantly 
lower among the children with T1D. 
In addition, the EURODIAB ACE Substudy 2 
study group 34 was comprised of eight centers in 
eastern and western Europe and reported data 
collected by interviews from five of the centers and 
by questionnaire from the other three. Probands 
with type 1 diabetes mellitus were compared with 
population-based controls.  Atopic Dermatitis (AD), 
and asthma in particular, were decreased in children 
with type 1 diabetes mellitus. The risk reductions 
associated with the atopic diseases were marked in 
children in the 10-14-year age group. 
Two sites in the United Kingdom, where the 
incidence of atopy was the highest, accounted for 
40% of the diabetics and may have contributed 
disproportionately to the study as a whole. 
Furthermore, only the western European centers 
demonstrated the inverse relationship between type 
1 diabetes mellitus and atopy, and the incidence of 
atopy was higher in the type 1 diabetes mellitus 
than controls in the Bulgarian cohort. Because 
atopy preceded type 1 diabetes mellitus, the 
authors’ inference that atopy may protect children 
from type 1 diabetes mellitus 34 may reflect the 
greater prevalence of atopy in western populations. 
Stromberg and colleagues41 compared 61 
Swedish children with type 1 diabetes mellitus to 
age- and sex-matched controls, and did not find a 
significant difference in the prevalence of atopic 
disease as defined by history, clinical features, skin 
prick test results, serum immunoglobulin E (IgE), 
or circulating IgE antibodies to allergens. 
Similarly, data from a 1987 Finnish registry42, a 
British health and nutrition survey43 and a Dutch 
cross-sectional survey44 found no differences in the 
cumulative incidence of asthma between type 1 
diabetes mellitus patients and controls. 
Perhaps the most provocative report is a 
retrospective case–controlled comparison of 928 
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Danish children with type 1 diabetes mellitus to a 
random sample of 10.000 population-based controls 
that found a lower cumulative incidence of AD in 
the diabetics45. Uniquely, this report showed the 
inverse correlation only among those diabetics who 
had AD prior to the onset of type 1 diabetes 
mellitus. 
Diabetics in whom the onset of AD followed 
type 1 diabetes mellitus were no different from 
controls. This study highlights a unique feature of 
type 1 diabetes mellitus relative to autoimmune 
diseases such as MS and RA: the pancreatic islet 
beta cells are diminished when type 1 diabetes 
mellitus presents46, such that the inflammation, 
while not completely resolved, has diminished to a 
level insufficient to affect other responses. The 
concept of waned type 1 inflammation after clinical 
presentation of type 1 diabetes mellitus is supported 
by high serum levels of IL-18, IFN-g and CXCL9 
(an IFN-γ inducible chemokine) in newly diagnosed 
diabetics compared with those with long-standing 
disease47 and low-risk controls48. Alternatively, 
defective regulatory mechanisms may make those 
with active type 1 diabetes mellitus equally prone to 
subsequent atopic or autoimmune disease. 
Consistent with the interpretation that active 
type 1 inflammation protects against clinical 
presentation of AD is a recent analysis of almost 
500.000 Israeli adults at the time of their enrolment 
into military service between 1980 and 2003. The 
diagnosis of asthma was confirmed by spirometry. 
Asthma prevalence and incidence were 
correlated inversely with a number of autoimmune 
diseases that were also diagnosed at enrolment49, 
suggesting that those with newly diagnosed 
autoimmunity were less prone to have asthma. 
Taken together, the studies that generalize the 
least and support the diagnoses with objective 
clinical and/or laboratory data suggest a model 
whereby Th1 inflammation suppresses the 
development of atopy45, while Th2 inflammation 
suppresses the severity and perhaps the onset of 
some autoimmune diseases50. 
In a study from Taiwan51, the prevalence of 
atopic diseases was compared in children with T1D 
and an age-matched control group. The prevalence 
of asthmatic symptoms in the T1D group was 
clearly lower than in the control group. However, 
the overall prevalence of atopy was not 
significantly different in these two groups. 
Symptoms of allergic rhinitis, including “nose 
symptoms with itchy watery eye in the past 12 
months”, and “hay fever or nasal allergy ever” were 
less prevalent in the T1D group. also in Taiwan 
study they compared data that aimed to determine 
whether occurrence of atopic diseases in T1D 
patients was associated with (passive) smoking, pet 
exposure, or breast feeding. They found no obvious 
association between atopy and these factors in T1D 
patients. 
 Hermansson et al.52 reported a lower 
probability of atopy in children with T1D, and their 
siblings as well, compared with control subjects. 
Moreover, Caffarelli et al. did not succeed in 
demonstrating an inverse relation between Th1- and 
Th2-mediated diseases in children with IgE 
sensitization or an atopic genetic predisposition53. 
Notably, the presence of T1D does not 
completely inhibit atopic diseases. In patients with 
multiple sclerosis, 4% had symptoms of atopic 
disease54. 
O'Driscoll et al also concluded that patients 
with rheumatoid arthritis had a normal prevalence 
of atopic diseases and there was no evidence that 
allergic factors contributed to the arthritis of the 
rheumatoid arthritis patients55. Therefore, the 
presence of a Th1-mediated disease was only one of 
the factors which influenced the presentation of 
atopic symptoms . 
The variation of atopy symptoms in T1D 
patients may be explained by the influence of some 
factors such as (passive) smoking, having pets and 
ever breast-feeding. These factors are known to 
influence atopic symptoms56-57. 
A recent survey of almost 500,000 Israeli adults 
at the time of their enrollment into military service 
between 1980 and 2003 found that asthma 
prevalence was inversely correlated with a number 
of autoimmune diseases that were also diagnosed at 
enrollment49. Moreover, the prevalence of various 
atopic symptoms (Table 1) showed no significant 
difference in the prevalence of atopic dermatitis, 
allergic rhinitis, conjunctivitis, hay fever, food 
allergy and asthma between the two groups. 
Although the prevalence of drug allergy, visit to an 
allergist, skin-prick test or RAST 
(radioallergosorbent) test was lower among T1DM 
patients as compared to control patients, this 
difference was not statistically significant . 
Cardwell et al.39 performed a meta-analysis 
summarizing the association between T1DM and 
atopic diseases (asthma, eczema, allergic rhinitis) in 
children. The analysis suggests that there is a small 
but significant reduction in the prevalence of 
asthma in children with T1DM, but the findings for 
the other atopic diseases are less conclusive. 
However, most of the studies were epidemiological 
and relied on patients’ and/or physicians’ reports 
rather than objective laboratory investigations such 
as IgE levels and sensitivity to aeroallergens. 
Elbarbary 
 42 
In addition to these epidemiological studies 
there is laboratory evidence that supports the 
Th1/Th2 paradigm. Rapaport and co-workers58 
reported that stimulated peripheral blood 
mononuclear cells of T1DM patients had early 
decreased secretion of Th2 cytokines and a late 
secretion of Th1 cytokines as compared to normal 
controls58. 
In contrast to the “traditional” concept of an 
inverse association between atopy and 
autoimmunity, some investigators have shown that 
autoimmune Th1 diseases such as thyroiditis, 
T1DM, celiac, psoriasis and rheumatoid arthritis in 
both adults and children could coexist with Th2-
mediated diseases41,43,59, suggesting that the 
Th1/Th2 paradigm is oversimplified. Furthermore, 
the increasing prevalence of atopic diseases 
worldwide is accompanied by a parallel rise in 
autoimmune Th1-mediated diseases such as 
T1DM60. Duran and colleagues59 found that atopy 
frequencies were similar in an adult population of 
type 1 diabetic patients and controls based on 
questionnaire, skin-prick test, pulmonary function 
test and methacholine challenge test. These studies 
together with our study are based on objective 
parameters rather than subjective evidence alone. 
In a Brazilian study61 the prevalence of allergic 
symptoms reported in their patients with T1DM 
was elevated as follows: rhinitis in 52.1% (alone 
20.8%; associated 31.8%), asthma in 22.9% and 
atopic eczema by 9.4%. Although there is no 
matched control group in this study, the prevalence 
of allergic rhinitis observed was higher than that 
documented among non-diabetic children (28.2%) 
and adolescents (27.4%) living in the south-central 
city of São Paulo, evaluated through the same 
instrument of evaluation, ISAAC WQ62. 
The prevalence of sensitisation (positive SPT) 
among T1DM patients identified as having allergic 
disease by ISAAC WQ was 72.6% distributed as 
follow: rhinitis 68.0%, asthma 59.1% ,and atopic 
eczema 44.4%. Among those with no allergic 
manifestation it was 20.6%. Analyzing the etiology 
between those with respiratory symptoms we 
observed higher frequency of sensitisation to dust 
mites (61.1%), followed by cat dander (27.8%) and 
Blattella germanica (16.7%). 
Although food allergens -mainly cow’s milk- 
have been studied as possible triggers for 
autoimmune disorder in T1DM, this subject is still 
controversial63,64. In the same study we found that 
food allergens had less relevance in the 
sensitization of patients, particularly among those 
with eczema: one patient was sensitive to soy and 
egg white and two patients were sensitive to 
peanuts. The sensitisation to cockroach allergens is 
a marker of severe asthma, more acute attacks, 
more hospitalizations and more frequent nocturnal 
symptoms. 
 
Table 1. Allergic symptoms among insulin dependent 
diabetes mellitus (IDDM) and control patients. 
 
Adopted from: Tirosh A, Mandel D, Mimouni FB, Zimlichman 
E, Shochat T, Kochba I. Autoimmune diseases in asthma. Ann 
Intern Med 2006; 144:877–83. 
 
Laboratory support 
Laboratory support for the previous findings came 
from two elegant studies published recently. Maier 
et al.65 investigated whether the Th2-related 
phenotype (total circulating IgE) and a Th1-
mediated disease (T1DM) share genetic loci. They 
found that allelic variation in the IL-13 gene is 
associated with IgE levels variance and atopic 
illness but has no detectable effect in type 1 
diabetes65. Heaton et al.66 reported that Th1 
cytokine secretion and not Th2 was associated with 
the size of immediate hypersensitivity skin test to 
allergens and bronchial hyper-responsiveness in a 
large cohort of T1DM children, suggesting that Th1 
cytokine secretion may either be pro- or anti-
inflammatory in the same autoimmune disease67,68. 
It should be mentioned that the small size of our 
groups prevents us from any definite conclusions, 
and that a larger sample size might have 
demonstrated a significant difference in some 
atopic categories. It is also possible that atopic 
manifestations in children with chronic disease such 
as T1DM are more readily diagnosed because of 
frequent medical visits. However, such a bias is 
unlikely in our study since our findings include also 
objective laboratory parameters in both groups. 
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The “classical” Th1/Th2 paradigm is currently 
undergoing increased scrutiny and includes, besides 
cytokines, other shared environmental and genetic 
risk factors that determine the balance between Th1 
and Th2 subsets and underlie the pathogenesis of 
atopy and autoimmune disorders. The parallel 
appearance of asthma and autoimmune conditions 
in the same patients may reveal aberrations of the 
immune system regulation instead of polarization 
towards Th1 or Th2 domination as a common 
pathophysiological mechanism. The new paradigm 
identifies additional lymphocyte subsets, such as 
Th17 T cells, which differentiate along a pathway 
that is totally independent of Th1 and Th2 cells, 
regulatory T cells (Treg), Th2-like natural killer T 
cells and novel soluble transcription factors21,69,70. 
Indeed the role of these cells in the pathogenesis of 




This review shows a lower prevalence of atopic 
disease in children with T1D compared with the 
control group, especially asthma. The results are 
consistent with the   study from Europe reporting 
that children with diabetes had fewer symptoms of 
asthma as well as atopic dermatitis compared with 
the background population. This suggests that the 
occurrence of Th1-mediated diseases may protect 
against the development of Th2-mediated atopic 
disease. Furthermore, investigation of the role of 
environmental factors is important in advancing 
understanding of the occurrence of atopic diseases 
in T1DM patients. It should be noted that 
environmental factors interacting with the genetic 
profile of each patient may be related to the natural 
history of both the T1DM as allergic diseases and, 
therefore, may be involved in some way in the 
coexistence of these diseases.  Moreover, it seems 
interesting to study further the association between 
the two pathologies to enable us to better evaluate 
the possible interrelationships between T1DM and 
allergy in order to understand which are the 
regulatory mechanisms of the immune system 
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